Topical Arousal Cream. A compounded vasoactive blend designed to act where it's applied.
Female sexual response is, in part, a vascular event. The genital tissues require dilated, well-perfused arterioles for the engorgement, sensitivity, and lubrication that characterize healthy arousal. When that vasodilation is sluggish — through age, hormonal shift, medication side effects, or chronic stress — the physical experience of arousal can lag behind desire.
Topical Arousal Cream is a compounded prescription product applied directly to the genital tissue. The formulation is built from well-characterized vasoactive ingredients — sildenafil, aminophylline, ergoloid mesylate, and pentoxifylline — chosen for their ability to increase local blood flow when applied to skin or mucosa.
Topical. Localized. Used as needed. Prescribed by a licensed provider after clinical review.
Topical Arousal Cream
Topical sildenafil and related vasoactive ingredients have a real, if still-developing, evidence base in female sexual function.
These are findings from peer-reviewed clinical trials of the active ingredients — applied topically — relevant to how this compounded formulation is designed.
Individual results vary. The Goldstein et al. trial did not meet its co-primary endpoints (SFQ28 Arousal Sensation domain and FSDS-DAO Q14) at the population level. Pre-specified exploratory endpoints at 8 weeks showed significant improvement in desire (p=0.02), with trending benefit in arousal lubrication (p=0.059) and orgasm (p=0.066). A follow-up analysis (Goldstein et al. 2024, Sexual Medicine, PMID 39564518) reported differential efficacy across age, race, and concomitant medication subgroups. Compounded Topical Arousal Cream is not FDA-approved for any sexual indication; it is prescribed off-label by a licensed provider following clinical review. Results are not guaranteed.
If you experience desire but the physical response feels disconnected, this is the category being studied.
Female Sexual Arousal Concerns
Desire is intact, but physical arousal — engorgement, lubrication, sensitivity — is delayed, blunted, or inconsistent. This pattern is the focus of recent topical-vasoactive research, including the published Phase 2b trial cited on this page.
Postpartum or Perimenopausal Tissue Changes
Hormonal transitions can shift genital tissue blood flow, sensitivity, and lubrication. A localized, vasodilatory approach can complement other treatments aimed at the same physiology.
SSRI-Related Sexual Side Effects
SSRIs and SNRIs are well-known to blunt sexual response. A topical, on-demand option avoids drug-drug interactions of additional systemic medications and can be discussed as part of an individualized plan.
Reduced Genital Sensation
If sensation has changed and feels muted, vascular contribution is one part of that picture. Topical vasoactive compounds increase local blood flow — the substrate of sensation and engorgement.
Lubrication Difficulties
Vaginal lubrication is partly a vascular event — engorged tissues produce transudate. A topical vasodilator can be a useful complement to lubricants for patients whose underlying issue is reduced local blood flow.
Want An On-Demand, Non-Hormonal Option
Used as needed before intimacy. No daily systemic medication. No hormone supplementation. A localized, prescribed approach for patients who prefer a more targeted intervention.
Prescribed For
Topical Arousal Cream vs. Oral PDE5 Inhibitor.
The same molecule can produce very different clinical effects depending on whether it acts systemically or locally. Topical formulations are designed for the local target tissue, with limited systemic exposure.
Topical Arousal Cream
Compounded • Sildenafil + Aminophylline + Ergoloid + Pentoxifylline
Oral PDE5 Inhibitor (off-label use in women)
Tablet • Sildenafil / Tadalafil
How four vasoactive ingredients combine to support local arousal physiology.
Sildenafil — PDE5 Inhibition
Sildenafil inhibits phosphodiesterase type 5, allowing nitric-oxide-mediated cyclic GMP to accumulate in vascular smooth muscle. Applied topically, the effect is concentrated at the application site — supporting the local vasodilation that underlies engorgement and lubrication. This is the same molecule used in topical formulations evaluated in published Phase 2b RCTs in female sexual arousal disorder.
Aminophylline + Pentoxifylline — Microvascular Flow
Aminophylline is a non-selective phosphodiesterase inhibitor and adenosine receptor antagonist; pentoxifylline is a methylxanthine that improves microvascular blood flow through rheologic and PDE-inhibition effects. Together they act on a different limb of the vascular pathway than PDE5 — supporting local perfusion via complementary mechanisms.
Ergoloid Mesylate — Alpha Blockade & Vasodilation
Ergoloid mesylate has alpha-adrenergic blocking activity and direct vasodilatory effects on small vessels. Adrenergic tone is one of the brakes on genital blood flow during stress — releasing that brake is part of the rationale for including ergoloid in a multi-target topical formulation aimed at the vascular component of arousal.
Safety and what to expect.
Topical formulations are designed to limit systemic exposure of the active ingredients. Here is what published trials and clinical use describe.
⚠ Important Cautions
Sildenafil is contraindicated in patients taking nitrates or guanylate cyclase stimulators (e.g., riociguat). Patients with significant cardiovascular disease, severe hepatic impairment, severe hypotension, or known hypersensitivity to any active ingredient should disclose those conditions during intake — your provider will determine whether the cream is appropriate. Compounded Topical Arousal Cream is not FDA-approved for any sexual indication; use is off-label and prescribed at provider discretion. Apply only to the area directed by your provider; avoid transfer to a partner where unintended exposure is undesired.
What to Expect — Topical Arousal Cream is used on-demand, typically applied to the genital tissue 15–30 minutes before intimacy. It is not a daily medication. Effects on arousal sensation, engorgement, and lubrication are highly individual and depend on the underlying physiology being addressed.
Common Reactions — Mild local effects reported include warmth, redness, mild irritation, or transient tingling at the application site. Systemic effects from a topical compound are typically lower than oral PDE5 inhibitors but can occur — headache, mild flushing, or nasal congestion are possible. Effects are short-lived in most patients.
Prescribed and monitored by your care team. All Obsidian Genetics prescriptions follow a licensed provider intake review. Your provider evaluates your health history and current medications — including nitrates and other vasoactive drugs — before prescribing. Compounded Topical Arousal Cream is personalized — formulation strength is matched to your needs and response.
Pricing
Topical Arousal Cream Protocol Pricing
One flat rate. Physician supervision, compounded medication, and ongoing support included.
Billed monthly. Cancel anytime.
All plans include: physician consultation · compounded medication · ongoing provider support · free shipping
Frequently asked question
What's actually in the cream?
Topical Arousal Cream is a compounded formulation of four vasoactive actives: sildenafil (PDE5 inhibitor), aminophylline (non-selective PDE inhibitor / adenosine receptor antagonist), ergoloid mesylate (alpha-blocker / vasodilator), and pentoxifylline (microvascular flow improver). Concentrations and exact composition are determined by your provider based on your intake. The product is prepared by a licensed compounding pharmacy.
How quickly does it work, and how long does the effect last?
Topical Arousal Cream is typically applied 15–30 minutes before intimacy. Local effects are reported in that window in clinical use. Duration varies and depends on the formulation strength, the patient’s underlying physiology, and the activity itself. It is not a long-acting medication.
Is this approved by the FDA?
Compounded Topical Arousal Cream is not FDA-approved for any sexual indication. It is a prescription product compounded by a licensed compounding pharmacy under your provider’s direction. Sildenafil is FDA-approved for other indications (erectile dysfunction, pulmonary arterial hypertension); the topical formulation studied in published Phase 2b trials is investigational. Use is off-label and prescribed at provider discretion.
What does the research show?
The most directly relevant trial is Goldstein et al. (2024, Obstetrics & Gynecology) — a randomized, double-blind, placebo-controlled Phase 2b trial of topical sildenafil cream 3.6% in 200 women with female sexual arousal disorder. The trial did not meet its co-primary endpoints (SFQ28 Arousal Sensation domain and FSDS-DAO Q14), but pre-specified exploratory endpoints at 8 weeks showed significant improvement in desire (p=0.02), with trending improvement in arousal lubrication (p=0.059) and orgasm (p=0.066) vs placebo. A subsequent subgroup analysis (Goldstein et al. 2024, Sexual Medicine, PMID 39564518) reported differential efficacy across age, race, and concomitant medication subgroups. The other actives in our compounded formulation (aminophylline, ergoloid mesylate, pentoxifylline) have established pharmacology supporting local vasodilation and are used here as part of a multi-target topical approach.
Is it safe? What about side effects?
Topical formulations are designed to limit systemic exposure of the active ingredients. The most commonly reported effects are local — mild warmth, redness, irritation, or tingling at the application site. Systemic effects are possible but typically lower than oral PDE5 inhibitors. Important contraindication: sildenafil should not be combined with nitrates or guanylate cyclase stimulators. Patients with significant cardiovascular disease, severe hepatic impairment, or known hypersensitivity should disclose those conditions during intake.
Will my partner be exposed?
Apply only to the area directed by your provider, and follow the application instructions provided with your prescription. Some transfer to a partner is possible during intimacy, particularly if the cream has not had time to absorb; the clinical relevance of that transfer is generally low at the doses used in compounded topical cream, but if you or your partner have specific medical concerns or are taking medications that interact with sildenafil (e.g., nitrates), discuss those with your provider before starting.
Prescription Medication Notice: Topical Arousal Cream is a compounded prescription product prepared by a licensed compounding pharmacy. It is prescribed by a licensed provider following a clinical review. Compounded Topical Arousal Cream is not FDA-approved for any sexual indication; use for sexual function is off-label and prescribed at provider discretion. Sildenafil is contraindicated in patients taking nitrates or guanylate cyclase stimulators. Disclose all medications and cardiovascular history during intake. Results are not guaranteed and individual outcomes vary.
Not Medical Advice: The content on this page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before starting any new treatment. All Obsidian Genetics prescriptions are issued following a clinical review by a licensed provider.
Citations & Evidence: Topical sildenafil cream Phase 2b RCT in female sexual arousal disorder: Goldstein et al., Obstetrics & Gynecology (2024); n=200 randomized double-blind placebo-controlled Phase 2b trial of topical sildenafil cream 3.6%; co-primary endpoints (SFQ28 Arousal Sensation domain and FSDS-DAO Q14) did not reach significance at the population level. Pre-specified exploratory endpoints at 8 weeks: significant improvement in desire (p=0.02), with trending benefit in arousal lubrication (p=0.059) and orgasm (p=0.066) vs placebo. Subgroup analysis: Goldstein et al., Sexual Medicine (2024); PMID 39564518 reported differential efficacy across age, race, and concomitant medication subgroups. Pharmacology of aminophylline (non-selective PDE inhibitor / adenosine receptor antagonist), ergoloid mesylate (alpha-adrenergic blocker / vasodilator), and pentoxifylline (microvascular flow improver / methylxanthine PDE inhibitor): standard pharmacology references.